The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Open accessAbstract
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142-144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, breakthrough infections have emerged in a small percentage of vaccine recipients, a phenomenon that has been described in other countries and health care institutions.6-8”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [8]
In the citing paper
“In contrast, reports in which certain variants of concern were more prevalent in breakthrough infections have been published as well.8,16,26”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationmRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Self-citationEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Self-citationSARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesPreprint
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.140871 · Cited by 600
Self-citationMeasuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Self-citationmRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–717 of 717
Xu, C., He, Z., Lei, W., Chen, L., Shen, D., Xiaofei, W., Xu, D., Xu, Y., & Huang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21532825
Wang, X.-J., Yao, L., Zhang, H.-Y., Zhu, K.-L., Zhao, J., Zhan, B.-D., Li, Y.-K., He, X.-J., Huang, C., Wang, Z.-Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22612648
Xu, C., He, Z., Lei, W., Chen, L., Shen, D., Wang, X., Xu, D., Xu, Y., & Huang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21532819
Puspitasari, M., Sattwika, P. D., Hidayat, A. R. P., Wijaya, W., Wardhani, Y., Intansari, U. S., Kertia, N., Purwanto, B., & Thobari, J. A. (2023) · Figshare · doi:10.6084/m9.figshare.23258778
Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24077073
Gärtner, K., Meleke, H., Kamdolozi, M., Chaima, D., Samikwa, L., Paynter, M., Nyirenda-Nyang’wa, M., Cloutman-Green, E., Nastouli, E., Klein, N. J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19695723
Ouarab, M., Rhazzar, Z., Touil, N., & Fahime, E. E. (2026) · COVID · doi:10.3390/covid6030050
Epidémiologie génomique des pathogènes au Sénégal : mycobacterium tuberculosis et SARS-CoV-2
Padane, A. (2023) · theses.fr (ABES) · doi:10.70675/e6b26f76z05baz4f66z9706zbde0e41a2626
Hernández, O., Naranjo, A. F., Vélez-Cadavid, J. J., Rosa, G. D. L., Gil, B., Moreno, A. M., Perez‐Restrepo, L. S., Úsuga, J., Aristizabal-Valencia, M., Saldarriaga, F. M., et al. (2026) · Vaccines · doi:10.3390/vaccines14050394 · Cited by 1
Prskawetz, A., Sánchez-Romero, M., & di Lego, V. (2022) · OSF Preprints (OSF Preprints)
Mir, M. A., Sharifi, P., Gila, F., Askari, H., Nourigorji, M., Zare, F., Karimi, S., Saadatian, Z., & Daraei, A. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01552-9
Liu, X., Yerragunta, V., Gorriparthi, S., Bonda, R. L., Mani, P., Tang, P. C. H., Pattnaik, P., Kanakasapapathy, A. K., Lingala, R., King, N. J. C., et al. (2026) · Vaccine X · doi:10.1016/j.jvacx.2026.100869
Tyagi, S., Singh, A. K., Tyagi, N., Chaturvedi, R., & Kushwaha, H. R. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100477
High-Throughput On-Chip Screening Enables Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution
He, Y., Yang, Z., Kuo, Y.-A., Wu, Y., Fonseca-Albert, D., Le, K. K., Guo, J., Wang, Y., Nguyen, A.-T., Chen, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c08330 · Cited by 1
Georgakopoulou, V., & Pitiriga, V. C. (2026) · Vaccines · doi:10.3390/vaccines14090812
Wang, M., Wang, W., Chen, Z., Lu, L., Liu, Z., & Jiang, S. (2026) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00100-25
Metadata
- Authors
- Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., Lifton, R., Nussenzweig, M. C., Hatziioannou, T., Bieniasz, P. D., & Darnell, R. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- From the Laboratory of Molecular Neuro-oncology (E.H., C.H., Y.S., N.E.B., M.B., E.G.C., R.B.D.), the Laboratory of Molecular Immunology (D.J.S.-B., C.G., M.C.N.), the Laboratory of Human Genetics and Genomics (R.L.), the Laboratory of Retrovirology (J.D., F.M., T.H., P.D.B.), and the Howard Hughes Medical Institute (M.C.N., P.D.B., R.B.D.), Rockefeller University, New York.
- Corresponding author
- Darnell, Robert B.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2212-2218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117968
- OpenAlex
- W3153636933
- Cited by
- 716
- References
- 11
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 42 · 2023: 102 · 2022: 298 · 2021: 239
- FWCI
- 54.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2 variants, breakthrough infection, COVID-19 vaccination, BNT162b2, mRNA-1273, E484K mutation, D614G mutation, viral genome sequencing, vaccine efficacy
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Aged, Antibodies, Viral, Female, Humans, Middle Aged, Mutation, Neutralization Tests, Phylogeny, Polymerase Chain Reaction, Sequence Analysis, RNA, Viral Load, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
